Anaplastic lymphoma kinase (ALK) alterations (activating mutations, amplifications, and
fusions/rearrangements) occur in~ 3.3% of cancers. ALK fusions/rearrangements are …

Progresses of systemic treatments in advanced non-small cell lung cancer (NSCLC), such
as immune checkpoint blockers (ICB) and targeted therapies, led to the increased incidence …

The diagnosis of brain metastases has historically been a dreaded, end-stage complication
of systemic disease. Additionally, with the increasing effectiveness of systemic therapies that …

PURPOSE Newer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer
(NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma …

Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous
system (CNS) metastases. Current treatments for this subgroup of patients with advanced …

Abstract Treatment with sotorasib has shown intracranial complete responses and continued
intracranial stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) …

Recent research has unveiled fascinating insights into the intricate mechanisms governing
tumor evolution. These studies have illuminated how tumors adapt and proliferate by …

Simple Summary In the current era of precision medicine, the management of patients with
brain metastases (BMs) is rapidly evolving. The technical evolution of radiotherapy, now …

Simple Summary Central nervous system (CNS) metastases are common and challenging
to manage among patients with non-small cell lung cancer (NSCLC). Here we provide an …

Purpose Although osimertinib has excellent intracranial activity in metastatic non-small cell
lung cancer (NSCLC) with exon 19 deletion or L858R EGFR alterations, measures of local …